1019results about "Senses disorder" patented technology

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

Provided herein are drug delivery systems and methods for locally delivering therapeutic agents, as well as methods for using such drug delivery systems for the treatment of disease.

The present invention relates to methods and compositions for editing an ABCA4 polynucleotide, e.g., an ABCA4 polynucleotide comprising a SNP associated with Stargardt Disease, type 1. The invention also relates to methods and compositions for treating or preventing Stargardt Disease, type 1, in a subject.

This invention belongs to the field of pharmaceutical formulation technology and provides a vinpocetine suspension and its preparation method. The vinpocetine suspension of this invention comprises the following raw materials in specific mass parts: vinpocetine, a suspending agent, a solubilizer, a stabilizer, and water. The vinpocetine suspension of this invention is suitable for oral administration. The excipients in the suspension include a suspending agent, a solubilizer, and a stabilizer. The solubilizer inhibits the aggregation of vinpocetine nanoparticles and improves the solubility and dispersion uniformity of vinpocetine nanoparticles in water. The suspending agent and stabilizer together construct a spatially stable structure, ensuring the suspension and dispersion of vinpocetine nanoparticles and resisting sedimentation. The suspending agent, solubilizer, and stabilizer work synergistically to achieve nanoscale distribution and uniform dispersion and suspension of vinpocetine, significantly improving the bioavailability of vinpocetine. High-pressure homogenization achieves nanoscale distribution of vinpocetine, with a particle size of 200-300 nm.

This invention relates to soba tertide (N succinyl-[Glu 9 ,Ala 11,15 This invention relates to a composition for promoting the proliferation and protection of existing neuroepithelium of cochlear and vestibular cells located within the otolaryngeal vesicle using endothelin B receptor agonists such as endothelin 1 (IRL-1620). The composition is administered systemically via transtympanic membrane, cochlear fenestration, or intravenously or intramuscularly. This invention also relates to a method for treating sensorineural hearing loss and vestibular symptoms caused by inner ear cell degeneration by using compounds containing endothelin analogs, through mechanisms of neuroprotection and neurogenesis of cochlear vestibular hair cells and synapses.

In certain embodiments, Formula I: 【Chemical 1】 Compounds of JPEG2025520456000046.jpg5339 or pharmaceutically acceptable salts or solvates thereof, compositions comprising a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and their use in the treatment of certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation) etc. are provided herein.

To provide a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of a disease involving ATX.SOLUTION: The invention provides a carboxylic acid compound represented by the general formula (1), or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

The present disclosure provides a construct comprising a coding sequence operably linked to a promoter, wherein the coding sequence encodes a vascular endothelial growth factor (VEGF) binding agent or a portion thereof. In some embodiments, a construct is an AAV construct. In some embodiments, an AAV construct is a part of an AAV particle. Compositions comprising constructs and AAV particles described herein can be useful in treating hearing loss, for example, hearing loss associated with vestibular schwannoma.

Providing nanoparticles for use in the treatment of eye diseases. [Solution] The present invention relates to nanoparticles for use in a method of effectively preventing or treating one or more inflammatory components, immune response components, angiogenic components and neuropathic components of retinal disease or optic neuropathy in patients, comprising: a core containing a drug having one or more of the following: anti-inflammatory activity, immunosuppressive activity, anti-angiogenic activity, neuroprotective activity, gene therapy activity and gene expression regulatory activity; an amphiphilic shell surrounding the core, the amphiphilic shell comprising at least one phospholipid and optionally at least one surfactant; and a targeted ligand covalently bound to the amphiphilic shell, which binds to receptors expressed on the surface of retinal pigment epithelial (RPE) cells and / or endothelial cells and / or optic nerve cells.

The present invention provides a pyridazine-3-carboxamide compound of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotope variant thereof. The present invention also provides a pharmaceutical composition comprising the compound, a method for preparing the same, and its use in the treatment or prevention of TYK2 kinase-mediated diseases. TIFF2025521070000079.tif42128

The present application provides a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, the traditional Chinese medicine composition comprises an active ingredient and an auxiliary material, wherein the active ingredient is prepared from the following raw materials: pollen typhae, salvia miltiorrhiza, rehmannia glutinosa, eclipta prostrata, chrysanthemum, scutellaria baicalensis, semen cassiae, plantago, herba lycopi, ligustrum lucidum, prunella vulgaris, gentiana, curcuma, equisetum, red peony root, cortex moutan, hawthorn, angelica sinensis, chuanxiong; wherein the auxiliary material can comprise dextrin; and the weight of dextrin is less than or equal to 1% based on the total weight of the active ingredient. The traditional Chinese medicine composition and the preparation method thereof can meet the requirements of the pharmaceutical process, have better fluidity, and are more conducive to the preparation of subsequent preparations.

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

Provided herein are ophthalmic pharmaceutical compositions, including compositions containing a fixed dose combination of active agents that are suitable for topical delivery to the eye(s) of a subject. In embodiments, the ophthalmic pharmaceutical compositions contain a glucocorticoid receptor agonist and an intraocular pressure lowering agent. Also provided are methods of manufacturing ophthalmic pharmaceutical compositions of the disclosure. Further provided are methods involving coadministration of a glucocorticoid receptor agonist and an intraocular pressure lowering agent, such as in the treatment of a patient suffering from an ocular condition.

This invention relates to antibody-drug conjugates and their uses. An antibody-drug conjugate having a structure represented by formula (I) is provided: Ab-(L-D) n (I), wherein Ab is an antibody against the interleukin-6 receptor or an antigen-binding fragment thereof, said antibody or antigen-binding fragment comprising at least one light chain and at least one heavy chain as described herein, and the use of the antibody-drug conjugate. The antibody-drug conjugate of the present invention can significantly reduce the dosage, improve patient tolerability, and reduce adverse reactions.

Polymeric ocular inserts are provided that can be dissolvable when placed in the fornix of the eye. These inserts can comprise one or more polymers and a softening agent / plasticizer such that when inserted into the eye, the polymers and softening agent / plasticizer can absorb tears, dissolve, and slowly release a lubricant into the tear film to lubricate and protect the ocular surface for a prolonged duration. Increasing the residence time on the ocular surface to achieve more sustained relief can decrease the frequency of dosing and the patient burden typically associated with topical drop usage. These polymeric ocular inserts can also comprise one or more pharmaceutically active agents.

The present application provides a VVN001-containing ophthalmic composition comprising an active material selected from a sodium salt represented by formula I and / or a free acid thereof, and ophthalmic excipients, to reduce the ocular inflammatory response by inhibiting a T cell-mediated inflammatory response through the active material. The concentration of the buffering agent in current invention is very low and the final buffer capacity of this ophthalmic composition is very close to the buffering capacity of the tear, which is tear-friendly and comfortable, and to increase the average residence time of the active material of the present application, as well as to increase the bioavailability of the active material represented by formula I according to the present application.

This disclosure relates to IGF1R antibodies and their applications. Specifically, this disclosure relates to antibodies that bind to IGF1R or antigen-binding fragments thereof, and the use of such antibodies or antigen-binding fragments in the diagnosis, prevention, or treatment of IGF1R-related diseases.

The present application belongs to the field of biomedical technology, and particularly relates to an axial length and growth trend evaluation method of eye axis based on PDGFRA gene and a PDGFRA enzyme activity control agent. The method comprises the following steps: 1) collecting an eye biological sample of a subject; 2) based on the expression level of PDGFRA gene of platelet-derived growth factor receptor alpha in the collected biological sample; 3) based on the expression level, calculating the axial length of the eye axis according to the quantitative relationship between the expression amount of PDGFRA and the axial length of the eye axis, and predicting the growth trend of the axial length of the eye axis through additional calculation. The technical scheme of the present application can effectively detect and evaluate the axial length of the eye axis, effectively judge the growth trend of the axial length of the eye axis, and directly and efficiently control the axial length of the eye axis and its growth trend through the existing drug components.

The application belongs to the technical field of pharmaceutical preparations, and discloses a trimetazidine hydrochloride tablet and a preparation process thereof.The trimetazidine hydrochloride tablet is composed of trimetazidine hydrochloride, lactose, microcrystalline cellulose, sodium crosslinked carboxymethyl cellulose and other auxiliary materials, and specific auxiliary components are added simultaneously.The preparation process comprises the following steps in sequence: pretreatment of core components, inclusion and dispersion, mixing of soft materials, granulation, drying, total mixing and tablet pressing, and the solubility and dispersibility of the drug are effectively improved.The trimetazidine hydrochloride tablet can realize rapid and sufficient release of the drug, has excellent content uniformity, provides precise and stable dose guarantee for clinical medication, and meets the clinical treatment requirements.

The application provides a fragrant trichosanthes fruit with dry eye alleviating function and a preparation method and application thereof, and belongs to the technical field of functional food processing. The preparation method of the fragrant trichoshanthes fruit comprises the following steps: S1, adding a fragrant raw material with homology of medicine and food into water, performing hot extraction treatment, and filtering to obtain a fragrant soaking solution; S2, mixing trichosanthes fruit and the fragrant soaking solution, taking out and draining after soaking, and performing low-temperature drying on the drained trichosanthes fruit to obtain the fragrant trichosanthes fruit. The obtained trichosanthes fruit has an effectively improved adverse flavor, and the palatability is significantly improved. In addition, through synergistic effect among raw materials, the fragrant trichosanthes fruit has the functions of improving tear secretion, regulating ocular surface indexes, and alleviating inflammation, and the like, and can improve and treat dry eye.

Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and / or an immune-related disorder.

The present invention relates to a crosslinkable liquid composition for use in a method of treating an eye disease of a subject eye, comprising (i) polyethylene glycol diacrylate (PEGDA), (ii) gelatin or a gelatin-based crosslinkable biomaterial, and (iii) a photoinitiator and optionally a coinitiator, the method comprising applying the crosslinkable liquid composition to the anterior corneal surface of the eye having the eye disease using a mold, crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a composition crosslinked on the anterior corneal surface of the eye, and correcting the curvature of the crosslinked composition.

The application discloses a tri-substituted tetrahydroisoquinoline amide derivative with a novel structure or a pharmaceutically acceptable salt thereof, which is a compound shown in formula I. The compound has a strong inhibiting capacity on immune cell migration, the compound itself has high permeability and good water solubility, and can be used as an immune cell migration inhibitor and used for developing a medicine for treating ophthalmic diseases such as dry eye.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The application discloses an eye preparation composition for treating presbyopia with longer action time and fewer adverse reactions and a preparation method thereof. The composition contains pilocarpine with a mass volume percentage of 0.42-1.02% (equivalent to 0.50-1.20% of hydrochloric acid pilocarpine and 0.55-1.33% of nitric acid pilocarpine), sodium carboxymethylcellulose with a mass percentage of 0.03-0.3%, hydroxyethyl p-henyl-ethyl ester with a mass percentage of 0.03-0.06%, and sodium chloride with a mass percentage of 0.6-0.8%. The prepared pilocarpine eye drops have the advantages of effectively enhancing the corneal permeability of pilocarpine, prolonging the retention time of the eye drops in eyes, reducing the use frequency while improving the pilocarpine miosis effect and treating presbyopia, reducing the irritation and damage of pilocarpine to corneas, and reducing the incidence of systemic adverse reactions compared with the related preparations on the market. In addition, the prescription pH value of the application is 4.0-5.0, which can effectively reduce the generation of impurities such as pilocarpine acid and ensure the product quality in the whole life cycle.

The present invention relates to: an AAV-based PDE6B viral vector for treating retinitis pigmentosa, the AAV-based PDE6B viral vector containing a tissue-specifically expressed PDE6A promoter; and a use of thereof, and provides a gene therapy for treating retinitis pigmentosa caused by PDE6B gene deficiency. The in vivo therapeutic efficacy of seven types of AAV5-PDE6B vectors was confirmed using an AAV by using a PDE6A promoter that is tissue-specifically expressed in photoreceptor rod cells that develop retinitis pigmentosa. An AAV5-PDE6A-450-PDE6B vector was selected as a candidate due to exhibiting strong tissue-specific expression in photoreceptor rod cells under even off-target conditions, unlike the gene expression characteristics of an AAV5-CMV-PDE6B vector, and was tested so as to be usable in the development of a gene therapeutic agent for treating PDE6B-deficient retinitis pigmentosa patients. Therefore, the present invention, related to AAV5-PDE6B for retinitis pigmentosa treatment and containing a tissue-specifically expressed PDE6A promoter, provides retinitis pigmentosa patients with an important treatment option having improved safety, and can be expected to have fundamental therapeutic effects compared to conventional treatments.